In the run-in phase, combined EGFR and ALK testing was performed in 95 out of 136 patients (69.9%, 95%CI: 61.4%-77.4%) with any stage of NSCLC, significantly more (p<0.001) than the estimated 55% in routine clinical care. The gene discussed is ALK; the disease is non-small cell lung carcinoma.